Related Experiment Video
Updated: Jun 29, 2025
06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.7K
2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis
Nicole K Bart1, Diane Fatkin2, James Gunton3
1Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. Electronic address: http://www.twitter.com/drnikkibart.
Heart, Lung & Circulation
|April 3, 2024
Summary
New diagnostic tools and disease-modifying therapies offer early intervention for cardiac amyloidosis (CA). Gene editing is emerging for this condition, with updates for Australian and New Zealand physicians.
Area of Science:
- Cardiology
- Genetics
- Internal Medicine
Background:
- Cardiac amyloidosis (CA) diagnosis and treatment have advanced significantly in the last five years.
- Non-invasive diagnostic tests and disease-modifying therapies are now available for early intervention.
- CA is among the first cardiomyopathies targeted by gene editing therapies.
Purpose of the Study:
- To provide an updated consensus statement on cardiac amyloidosis for Australian and New Zealand physicians.
- To review the latest advances in the diagnosis, investigation, and management of CA.
- To contextualize emerging CA therapies within the Australian and New Zealand healthcare landscape.
Main Methods:
- Review of recent scientific literature on cardiac amyloidosis diagnosis and treatment.
- Analysis of the current and potential future availability of CA therapies in Australia and New Zealand.
- Development of consensus recommendations for clinical practice.
Main Results:
- Significant progress in non-invasive diagnostic methods for CA.
- Emergence of disease-modifying therapies, including gene editing, offering new treatment avenues.
- Rapid evolution of the field necessitates updated clinical guidance.
Conclusions:
- Early diagnosis and intervention are crucial for improving outcomes in cardiac amyloidosis.
- Emerging therapies hold significant promise but require careful consideration of accessibility and implementation in Australia and New Zealand.
- This consensus statement provides essential updates for healthcare professionals managing CA.
